/stocks — the workspaceLOADING
All TCRT SEC filings, by type → · Earnings date & implied move · Search inside filings
Alaunos Therapeutics, Inc. (TCRT) is a pharmaceutical preparations company. Piotroski F-Score 3/8. 5 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind TCRT’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from TCRT’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on TCRT plus an auto-SWOT — built from TCRT's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate TCRT using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has TCRT been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as TCRT tagged it: revenue us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
No tracked institution reported a position in TCRT in the latest 13F round.
Projected from TCRT's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentTCRT files or announces.
| Reported | Close-to-close |
|---|---|
| 2024-10-10 | -4.1% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
None of the 5 estimators could run on TCRT's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for TCRT. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for TCRT, so sector medians could not fill the gaps.
Every refusal recorded for TCRT → · How often we decline, and why →
No lawmaker has disclosed a trade in TCRT under the STOCK Act.
Head office: Fort Lauderdale, Florida, United States · the company’s charter and its head office are in different states.
A charter change was filed after this. An 8-K filed 2026-09-17 reports an amendment to the company’s articles and a change to shareholder rights (Items 5.03 and 3.03). Reincorporations are reported that way, but so are routine changes such as a new series of preferred stock, and we have not read this one. If it moved the company, the next periodic report’s cover will show it.
Source: the cover page of Alaunos Therapeutics, Inc.’s 10-Q filed 2026-08-14, on EDGAR. Filings checked 2026-10-25. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No open-market Form 4 buys or sells reported for TCRT in the last ~6 months.
2 of the 2 checks that ran found nothing new for TCRT. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.